Australia's most trusted source of pharma news
Earlier
Aust biosims battle moves online
Posted 29 September 2017
With AbbVie's Humira (adalimumab) nearing the end of its Australian patent and the first biosimilar for the rheumatoid arthritis blockbuster recently approved in the US, the pharmaco has moved to protect its local market with an online educational course for pharmacists entitled 'Understanding Biologic Medicines'.
Run in conjunction with the Pharmacy Guild, the online course comes just two weeks after the Guild's biosimilars education campaign entitled 'Biosimilars in Focus' was launched in conjunction with MSD, PBS sponsor of etanercept biosimilar Brenzys.
Along with an online course specifically about Brenzys, the biosimilars course is aimed squarely at community pharmacists. PBS-listed in March, Brenzys is the first biosimilar expected to be largely dispensed by community pharmacists.
According to the Pharmacy Guild, the new biologics course, which has been accredited for one hour of Group 1 continuing professional development (CPD) credit, will examine the evolving landscape and key clinical considerations regarding biologic medicines.
AbbVie's general manager Kirsten O'Doherty said the course would play an important role in supporting pharmacists to further develop their understanding of biologic medicines, ensuring they were confident when having conversations about the key clinical considerations related to the therapeutic use of these complex medicines.
"AbbVie is committed to helping pharmacists have resources and training so they can best meet the needs of the patients they serve," she said.
Speaking about the education initiative, Pharmacy Guild national president George Tambassis pointed out that in the very near future biologics would become a significant part of the medicines supplied by community pharmacy and pharmacists needed to have a comprehensive understanding of both biologics and biosimilars.
Earlier this year there was a minor battle for the hearts and minds of pharmacists in the run up to the Brenzys PBS-listing with GBMA CEO Belinda Wood voicing concern about both the vacuum in biosimilar education and "misinformation" she believed was being propagated by some innovator pharmacos.
David Rowley
david.rowley@lushmedia.com.au
Posted 29 September 2017
With AbbVie's Humira (adalimumab) nearing the end of its Australian patent and the first biosimilar for the rheumatoid arthritis blockbuster recently approved in the US, the pharmaco has moved to protect its local market with an online educational course for pharmacists entitled 'Understanding Biologic Medicines'.
Run in conjunction with the Pharmacy Guild, the online course comes just two weeks after the Guild's biosimilars education campaign entitled 'Biosimilars in Focus' was launched in conjunction with MSD, PBS sponsor of etanercept biosimilar Brenzys.
Along with an online course specifically about Brenzys, the biosimilars course is aimed squarely at community pharmacists. PBS-listed in March, Brenzys is the first biosimilar expected to be largely dispensed by community pharmacists.
According to the Pharmacy Guild, the new biologics course, which has been accredited for one hour of Group 1 continuing professional development (CPD) credit, will examine the evolving landscape and key clinical considerations regarding biologic medicines.
AbbVie's general manager Kirsten O'Doherty said the course would play an important role in supporting pharmacists to further develop their understanding of biologic medicines, ensuring they were confident when having conversations about the key clinical considerations related to the therapeutic use of these complex medicines.
"AbbVie is committed to helping pharmacists have resources and training so they can best meet the needs of the patients they serve," she said.
Speaking about the education initiative, Pharmacy Guild national president George Tambassis pointed out that in the very near future biologics would become a significant part of the medicines supplied by community pharmacy and pharmacists needed to have a comprehensive understanding of both biologics and biosimilars.
Earlier this year there was a minor battle for the hearts and minds of pharmacists in the run up to the Brenzys PBS-listing with GBMA CEO Belinda Wood voicing concern about both the vacuum in biosimilar education and "misinformation" she believed was being propagated by some innovator pharmacos.
David Rowley
david.rowley@lushmedia.com.au
Drought, fire and now virus cut chance of PBS relief.
Don't do it for the accolades; do it for your kids.
New forms of rotavirus vaccine Rotarix.